Exorex Lotion 5% v-in-w Cutaneous Emulsion: Indications, Dosage, Precautions, Adverse Effects
Россия
  • Россия
  • Украина

Exorex Lotion 5% v-in-w Cutaneous Emulsion - Product Information

Manufacture: Forest Laboratories, Inc.
Country: Belgium
Condition: Itching (Pruritus), Psoriasis
Class: Miscellaneous topical agents
Form: Cream, gel, liniment or balm, lotion, ointment, etc
Ingredients: coal tar solution 5% v/w, polysorbate 80, ethanol, dl-alpha tocopherol, xanthan gum, vitamin F ethyl ester, hydrogenated polyoxyl castor oil, propyl hydroxybenzoate (E216), methyl hydroxybenzoate (E218), purified water

Name of the Medicinal Product

Exorex Lotion 5% v/w Cutaneous Emulsion

Qualitative and Quantitative Composition

The active ingredient is coal tar solution 5% v/w.

Excipients with known effect:

Methyl hydroxybenzoate (E218) 0.10% w/w

Propyl hydroxybenzoate (E216) 0.05% w/w

Hydrogenated polyoxyl castor oil 0.45% w/w

For the full list of excipients, see section List of Excipients.

Pharmaceutical Form

Cutaneous emulsion

A smooth mustard coloured emulsion.

Clinical Particulars

Therapeutic Indications

Exorex is for the treatment of psoriasis of the skin and scalp.

Posology and Method of Administration

Adults and Children Over 12 Years of Age

Ensure that the lesions are clean. Apply a thin layer of Exorex two to three times per day to the affected areas. Massage gently and leave to dry.

For Young Children Under 12 Years of Age and the Elderly

The emulsion may be diluted by mixing with a few drops of freshly boiled and cooled water in the palm of the hand.

Contraindications

Hypersensitivity to the active substance or to any of the excipients listed in section List of Excipients.

Presence of folliculitis and acne vulgaris.

Exorex should not be used on patients who have disease characterised by photosensitivity such as lupus erythematosus or allergy to sunlight.

Exorex should not be applied to inflamed or broken skin (open exuding wounds or infection of the skin).

Special Warnings and Precautions for Use

Coal tar may cause skin irritation. If irritation occurs, the treatment should be reviewed and discontinued if necessary.

Coal tar enhances photosensitivity of the skin, and exposure to direct sunlight after application of Exorex should be avoided.

Use with care near the eyes and mucous membranes. If any emulsion should accidentally enter the eye, flush with normal saline solution or water.

Do not apply to genital and rectal areas.

Apply with caution to the face.

Hydrogenated polyoxyl castor oil may cause skin reactions. Methyl and propyl hydroxybenzoates may cause allergic reactions that might be delayed.

Interaction with Other Medicinal Products and Other Forms of Interaction

None known

Fertility, Pregnancy and Lactation

There is inadequate evidence of safety in pregnant and lactating women but coal tar preparations have been in use for many years without apparent ill-consequence and no harmful effects on the health of the child is anticipated with the proper use of this product. However, it is recommended that the use of coal tar in pregnancy and lactation be restricted to intermittent use, in a low concentration on a relatively small percentage of body surface and that use during the first trimester be avoided.

Effects on Ability to Drive and Use Machines

None known

Undesirable Effects

Skin and subcutaneous tissue disorders:

Skin irritation, photosensitivity of the skin. In addition coal tar may cause acne-like eruptions of the skin.

An increased risk of skin cancer in psoriatic patients treated with a combination of coal tar and UVB radiation has been reported. However epidemiological studies of patients treated with coal tar alone are inconclusive. The risk of toxicity should be taken into account when considering the suitability of this product for the patient (see also section 5.3).

Reporting of Suspected Adverse Reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard.

Overdose

There is no evidence that overdose of topical Exorex would be harmful other than possibly inducing a hypersensitivity to coal tar. Ingestion of Exorex may require gastric lavage depending on the quantity taken and should be treated symptomatically.

Pharmacological Properties

Pharmacodynamic Properties

Pharmacotherapeutic group: Tars, ATC code: D05AA

Exorex contains coal tar, an antipruritic and keratoplastic. It is used in eczema, psoriasis and other skin conditions. Tar acids have also been shown to have disinfectant properties. Exorex may be used alone, or as part of a more extensive treatment regimen.

Pharmacokinetic Properties

Not applicable.

Preclinical Safety Data

In animal studies coal tar has been shown to increase the incidence of epidermal carcinomas and self-limiting keratoacanthomas.

While the ingredients of coal tar have been shown to express genotoxic properties, epidemiological studies with patients have been shown to be inconclusive concerning the potential carcinogenic risks of coal tar products in human long term treatment. Nevertheless the possible risk of prolonged treatment should be taken into account when considering the usage of the product.

Pharmaceutical Particulars

List of Excipients

Polysorbate 80

Ethanol

dl-Alpha tocopherol

Vitamin F ethyl ester

Xanthan gum

Propyl hydroxybenzoate (E216)

Methyl hydroxybenzoate (E218)

Hydrogenated polyoxyl castor oil

Purified water

Incompatibilities

Not applicable

Shelf Life

2 years

Special Precautions for Storage

Do not store above 25°C.

Nature and Contents of Container

High density polyethylene bottle containing titanium dioxide.

Polypropylene green flip-top caps.

Pack sizes: 100 and 250ml

A professional sales pack of 30ml is also available.

Not all pack sizes may be marketed.

Special Precautions for Disposal and Other Handling

Shake the bottle before use.

Marketing Authorisation Holder

Forest Tosara Limited

Baldoyle Industrial Estate

Grange Road

Dublin 13

Ireland

Marketing Authorisation Number(s)

PL 06166/0001

Date of First Authorisation/Renewal of the Authorisation

3 November 1999/23 May 2007

Date of Revision of the Text

29/10/2015

Company Contact Details

Forest Laboratories UK Limited (a subsidiary of Actavis PLC)

http://www.actavis.co.uk

Address

Whiddon Valley, Barnstaple, Devon, EX32 8NS, UK

Fax

+44 (0)1271 346106

Medical Information e-mail

medinfo@actavis.co.uk

Telephone

+44 (0)1271 311 200

Medical Information Direct Line

+44(0)1271 385 257